Patheon IncTSX: PTI

CEPH International Files Response to FDA Warning Letter

· Issued by Patheon Inc via CNW
TORONTO, Oct. 6 /CNW/ - Patheon Inc. (TSX: PTI) today announced that its
subsidiary, CEPH International Corporation, has filed its response letter to
the US Food & Drug Administration (FDA) in connection with the Warning Letter
it received on September 16, 2005.
Results for the fourth quarter ending October 31, 2005 are expected to be
negatively impacted by approximately 3 cents per share as a result of the
decision, taken by CEPH after receipt of the Warning Letter, to suspend
production of the Omnicef powder for oral suspension product and the
additional costs incurred to address the matter.
CEPH, with the assistance of experts from Patheon, its client and
external consultants worked diligently to analyze the issues raised by the FDA
and to develop an enhanced process improvement program to address the FDA's
concerns. CEPH is currently implementing process improvements consistent with
the program outlined in the response letter to the FDA. Although Patheon
currently anticipates that it will re-commence normal production of the
Omnicef powder for suspension product in the first quarter of its 2006 fiscal
year, the actual timing will be dependent on the FDA's response to CEPH's
response letter.

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical
Corporation, acquired in December 2004, Patheon operates a network of 14
facilities in the United States, Canada and Europe, employing more than 5,900
people and serving a client base of 180 pharmaceutical and biotechnology
companies.

This news release contains forward-looking statements with respect to
Patheon, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular our clients), the
impact of changes in pharmaceutical development and manufacturing regulations
and general economic and market factors (including inflation and changes in
laws) and other factors discussed in materials filed with applicable
securities regulatory authorities from time to time.
%SEDAR: 00001700E

Patheon Inc on 6ix

Story so far

Earlier from Patheon

Later from Patheon

All Patheon news releases